Literature DB >> 19935785

Severe complications limit long-term clinical success of self-expanding metal stents in patients with obstructive colorectal cancer.

Gloria Fernández-Esparrach1, J M Bordas, M D Giráldez, A Ginès, M Pellisé, O Sendino, G Martínez-Pallí, A Castells, J Llach.   

Abstract

OBJECTIVES: Self-expanding metal stents (SEMS) are increasingly being used to treat malignant colorectal obstruction. However, complications have been reported in up to 50% of patients. There is limited information on long-term outcomes of these patients. The aim of this study was to retrospectively assess the long-term clinical success of SEMS in patients with malignant colorectal obstruction in a single tertiary center and to identify possible predictive factors of developing complications.
METHODS: A total of 47 attempts to insert colorectal SEMS were made in 47 patients during a 5-year period. Stents of 9-cm length were placed under endoscopic and radiologic monitoring. After 24 h, all patients underwent abdominal X-ray to verify correct positioning of the stent. Patients were followed at the outpatient clinic.
RESULTS: Insertion success was achieved in 44 (94%) patients. Acceptable initial colonic decompression was observed in 44 out of 47 (94%) attempts and in all (100%) successfully inserted stents. The stents were placed in the rectum (n=7, 15%), sigmoid (n=33, 70%), left colon (n=4, 9%), or anastomosis (n=3, 6%). The majority of patients had stage IV disease (n=40, 85%). SEMS served as a bridge to scheduled surgery in 9 (20%) patients and as a palliative definitive treatment in 38 (80%) cases. Three patients were lost to follow-up, so the outcome was evaluated in 41 patients. Long-term clinical failure occurred in 21 (51%) patients and was due to complications such as: migration (n=9, 22%), obstruction (n=7, 17%), perforation (n=3, 7%), and tenesmus (n=2, 5%). Perforations occurred 3, 4, and 34 days after insertion, and all patients died. In the bridge-to-surgery group, primary anastomosis was possible in only four of nine patients (44%). Clinical failure was not associated with any tumor-related factor. However, eight of nine patients with stent migration and two of three patients with perforation had been previously treated with chemotherapy.
CONCLUSIONS: Placement of SEMS does not seem to be as effective as suggested because of late complications. For patients with potentially curable lesions, the use of colonic stents for malignant obstruction should only be considered when surgery is scheduled shortly after the stent insertion. Moreover, in patients with incurable obstructing colorectal cancer eligible for chemotherapy and a long life expectancy, palliative treatments other than SEMS should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935785     DOI: 10.1038/ajg.2009.660

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  45 in total

1.  The role of stents in obstructive colorectal cancer.

Authors:  Gloria Fernández Esparrach
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-06

Review 2.  Stents for colorectal obstruction: Past, present, and future.

Authors:  Eui Joo Kim; Yoon Jae Kim
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

3.  Stenting in malignant colonic obstruction--is it a real therapeutic option?

Authors:  Nir Horesh; Joseph Yosef Dux; Moshe Nadler; Alon Lang; Oded Zmora; Einat Shacham-Shmueli; Mordechai Gutman; Ron Shapiro
Journal:  Int J Colorectal Dis       Date:  2015-08-28       Impact factor: 2.571

4.  Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society.

Authors:  Luca Ansaloni; Roland E Andersson; Franco Bazzoli; Fausto Catena; Vincenzo Cennamo; Salomone Di Saverio; Lorenzo Fuccio; Hans Jeekel; Ari Leppäniemi; Ernest Moore; Antonio D Pinna; Michele Pisano; Alessandro Repici; Paul H Sugarbaker; Jean-Jaques Tuech
Journal:  World J Emerg Surg       Date:  2010-12-28       Impact factor: 5.469

5.  Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis.

Authors:  Xiao-Dan Zhao; Bao-Bao Cai; Ri-Sheng Cao; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 6.  Role of stenting in gastrointestinal benign and malignant diseases.

Authors:  Benedetto Mangiavillano; Nico Pagano; Monica Arena; Stefania Miraglia; Pierluigi Consolo; Giuseppe Iabichino; Clara Virgilio; Carmelo Luigiano
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

Review 7.  Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review.

Authors:  Amal Imbulgoda; Anthony MacLean; John Heine; Sebastien Drolet; Michael M Vickers
Journal:  Can J Surg       Date:  2015-06       Impact factor: 2.089

8.  A prospective evaluation of short-term and long-term results from colonic stenting for palliation or as a bridge to elective operation versus immediate surgery for large-bowel obstruction.

Authors:  Luca Gianotti; Nicolò Tamini; Luca Nespoli; Matteo Rota; Elisa Bolzonaro; Roberto Frego; Alessandro Redaelli; Laura Antolini; Antonella Ardito; Angelo Nespoli; Marco Dinelli
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

9.  Clinical outcomes following secondary self-expandable metal stent (SEMS) insertion due to previous stent migration in malignant colorectal obstruction.

Authors:  A Ra Choi; Jin Young Yoon; Hyun Jung Lee; Hui Won Jang; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Surg Endosc       Date:  2013-03-22       Impact factor: 4.584

10.  Covered self-expandable metal stents are more associated with complications in the management of malignant colorectal obstruction.

Authors:  Jae Hyuk Choi; Yoo Jin Lee; Eun Soo Kim; Jong Hwan Choi; Kwang Bum Cho; Kyung Sik Park; Byoung Kuk Jang; Woo Jin Chung; Jae Seok Hwang
Journal:  Surg Endosc       Date:  2013-03-14       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.